查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1387358

抗憂鬱症市場報告：2030 年趨勢、預測與競爭分析

Antidepressant Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

抗憂鬱症趨勢和預測

預計到 2030 年，全球抗憂鬱症市場將達到約 218 億美元，2024 年至 2030 年複合年成長率為 5.3%。這個市場的主要促進因素是全球憂鬱症、強迫性精神官能症和其他情緒障礙盛行率的上升，以及人們對心理健康意識的增強。全球抗憂鬱症市場前景看好，重度憂鬱症、強迫性精神官能症、整體焦慮症、恐慌症市場蘊藏著商機。

抗憂鬱症市場洞察

Lucintel 預測，由於重度憂鬱症和焦慮症的增加，選擇性血清素再回收抑制劑在預測期內仍將是最大的區隔市場。

在這個市場中，重度憂鬱症仍然是最大的部分，因為它的盛行率很高，而且年輕人對憂鬱症治療和管理的認知不斷提高。

由於憂鬱症患者數量不斷增加、老年人口迅速成長以及該地區主要企業的存在，北美在預測期內可能仍然是最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1. 區隔市場中最有前途和高成長的機會是什麼？
  • Q.2. 未來哪個區隔市場成長較快？為什麼？
  • Q.3.哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要課題和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去五年發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章執行摘要

第2章全球抗憂鬱症市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與課題

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球抗憂鬱症市場趨勢（2018-2023）與預測（2024-2030）
  • 全球抗憂鬱症市場（依產品）
    • 三環抗憂鬱藥物
    • 選擇性血清素再回收抑制劑
    • 血清素去甲腎上腺素再回收抑制劑
    • 單胺氧化酶抑制劑
    • 血清素拮抗劑/再回收抑制劑
    • 其他
  • 依憂鬱症分類的全球抗憂鬱症市場
    • 重度憂鬱症
    • 強迫性精神官能症
    • 整體焦慮症
    • 恐慌症
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球抗憂鬱症市場區域分佈
  • 北美抗憂鬱症市場
  • 歐洲抗憂鬱症市場
  • 亞太地區抗憂鬱症市場
  • 其他地區抗憂鬱症市場

第5章競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球抗憂鬱症市場成長機會（依產品）
    • 憂鬱症帶來的全球抗憂鬱症市場成長機會
    • 全球抗憂鬱症市場成長機會（依地區）
  • 全球抗憂鬱症市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球抗憂鬱症市場的產能
    • 全球抗憂鬱症市場的合併、收購與合資企業
    • 認證和許可

第7章主要企業概況

  • Alkermes
  • AbbVie
  • Eli Lilly
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • H. Lundbeck
  • Merck
簡介目錄

Antidepressant Trends and Forecast

The future of the global antidepressant market looks promising with opportunities in the major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder markets. The global antidepressant market is expected to reach an estimated $21.8 billion by 2030 with a CAGR of 5.3% from 2024 to 2030. The major drivers for this market are rising prevalence of depression, obsessive-compulsive disorder, and other mood disorders across the globe and growing awareness about mental health.

A more than 150-page report is developed to help in your business decisions.

Antidepressant by Segment

The study includes a forecast for the global antidepressant by product, depressive disorder, and region.

Antidepressant Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Tricyclic Antidepressants
  • Selective Serotonin Reuptake Inhibitors
  • Serotonin-Norepinephrine Reuptake Inhibitors
  • Monoamine Oxidase Inhibitors
  • Serotonin Antagonist & Reuptake Inhibitors
  • Others

Antidepressant Market by Depressive Disorder [Shipment Analysis by Value from 2018 to 2030]:

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

Antidepressant Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Antidepressant Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies antidepressant companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the antidepressant companies profiled in this report include-

  • Alkermes
  • AbbVie
  • Eli Lilly
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • H. Lundbeck
  • Merck

Antidepressant Market Insights

Lucintel forecasts that selective serotonin reuptake inhibitor will remain the largest segment over the forecast period due to rising occurrence of major depressive disorder and anxiety disorders.

Within this market, major depressive disorder will remain the largest segment due to high prevalence of major depressive disorder and increasing awareness towards treatment and management of depression among youth population.

North America will remain the largest region over the forecast period due to increasing cases of depression, surge in the geriatric population, and presence of major players in the region.

Features of the Global Antidepressant Market

Market Size Estimates: Antidepressant market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Antidepressant market size by product, depressive disorder, and region in terms of value ($B).

Regional Analysis: Antidepressant market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, depressive disorders, and regions for the antidepressant market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the antidepressant market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the antidepressant market size?

Answer: The global antidepressant market is expected to reach an estimated $21.8 billion by 2030.

Q2. What is the growth forecast for antidepressant market?

Answer: The global antidepressant market is expected to grow with a CAGR of 5.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the antidepressant market?

Answer: The major drivers for this market are rising prevalence of depression, obsessive-compulsive disorder, and other mood disorders across the globe and growing awareness about mental health.

Q4. What are the major segments for antidepressant market?

Answer: The future of the antidepressant market looks promising with opportunities in the major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder markets.

Q5. Who are the key antidepressant market companies?

Answer: Some of the key antidepressant companies are as follows:

  • Alkermes
  • AbbVie
  • Eli Lilly
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • H. Lundbeck
  • Merck

Q6. Which antidepressant market segment will be the largest in future?

Answer: Lucintel forecasts that selective serotonin reuptake inhibitor will remain the largest segment over the forecast period due to rising occurrence of major depressive disorder and anxiety disorders.

Q7. In antidepressant market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing cases of depression, surge in the geriatric population, and presence of major players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the antidepressant market by product (tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist & reuptake inhibitors, and others), depressive disorder (major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Antidepressant Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Antidepressant Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Antidepressant Market by Product
    • 3.3.1: Tricyclic Antidepressants
    • 3.3.2: Selective Serotonin Reuptake Inhibitors
    • 3.3.3: Serotonin-Norepinephrine Reuptake Inhibitors
    • 3.3.4: Monoamine Oxidase Inhibitors
    • 3.3.5: Serotonin Antagonist & Reuptake Inhibitors
    • 3.3.6: Others
  • 3.4: Global Antidepressant Market by Depressive Disorder
    • 3.4.1: Major Depressive Disorder
    • 3.4.2: Obsessive-Compulsive Disorder
    • 3.4.3: Generalized Anxiety Disorder
    • 3.4.4: Panic Disorder
    • 3.4.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Antidepressant Market by Region
  • 4.2: North American Antidepressant Market
    • 4.2.2: North American Antidepressant Market by Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others
  • 4.3: European Antidepressant Market
    • 4.3.1: European Antidepressant Market by Product: Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors, and Others
    • 4.3.2: European Antidepressant Market by Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others
  • 4.4: APAC Antidepressant Market
    • 4.4.1: APAC Antidepressant Market by Product: Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors, and Others
    • 4.4.2: APAC Antidepressant Market by Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others
  • 4.5: ROW Antidepressant Market
    • 4.5.1: ROW Antidepressant Market by Product: Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors, and Others
    • 4.5.2: ROW Antidepressant Market by Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Antidepressant Market by Product
    • 6.1.2: Growth Opportunities for the Global Antidepressant Market by Depressive Disorder
    • 6.1.3: Growth Opportunities for the Global Antidepressant Market by Region
  • 6.2: Emerging Trends in the Global Antidepressant Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Antidepressant Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Antidepressant Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Alkermes
  • 7.2: AbbVie
  • 7.3: Eli Lilly
  • 7.4: F. Hoffmann-La Roche
  • 7.5: GlaxoSmithKline
  • 7.6: H. Lundbeck
  • 7.7: Merck